BRIEF

on BIOSYNEX (EPA:ALBIO)

BIOSYNEX initiates financial restructuring and will liquidate its subsidiary AVALUN

Stock price chart of BIOSYNEX (EPA:ALBIO) showing fluctuations.

BIOSYNEX has announced the opening of a safeguard procedure approved by the Strasbourg Judicial Court. This decision aims to restructure its financial liabilities. This will allow BIOSYNEX to begin negotiations with financial partners under a protective framework. During the procedure, the company's previous liabilities will be frozen.

The judicial administrator, Maître WEIL of SAS WEIL – GUYOMARD – LUTZ, has been appointed to supervise the company, while Maître FLESCH of SELARL MJ SYNERGIE will serve as judicial receiver. Furthermore, the AVALUN subsidiary will benefit from compulsory liquidation following a declaration of cessation of payments. BIOSYNEX will regularly inform the market of the progress of these proceedings.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all BIOSYNEX news